<DOC>
	<DOCNO>NCT01005355</DOCNO>
	<brief_summary>This trial test investigational drug IMC-1121B administer Japanese participant advance solid tumor respond standard therapy standard therapy available . The rationale perform trial establish safety profile pharmacokinetics IMC-1121B .</brief_summary>
	<brief_title>Study IMC-1121B Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This single center , open-label , single-arm , Phase 1 study enroll approximately 15 18 participant . The actual size vary depend dose-limiting toxicity ( DLTs ) observe resultant size cohort . Participants receive IMC-1121B , administer intravenously , every 2 3 week 6 week ( one cycle ) . After one cycle treatment , participant objective response stable disease may continue receive IMC-1121B dose schedule disease progression withdrawal criterion meet . A minimum three participant enrol cohort . Dose escalation successive cohort occur participant complete one cycle therapy . Participants enrol sequentially cohort . A complete participant either participant completes initial 6 week treatment period ( Cycle 1 ) participant discontinues therapy IMC-1121B related toxicity Cycle 1 . Participants complete first 6 week treatment reason IMC-1121B -related toxicity replace . Toxicity data cohort review prior dose escalation . Upon completion require safety evaluation initial 6 week , next cohort new participant treat next high dose level use dose escalation scheme .</detailed_description>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>Solid tumor participant histopathologically cytologically document . Advanced primary recurrent solid tumor participant responded standard therapy standard therapy available . The participant measurable nonmeasurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) . The participant Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) score 01 study entry . The participant able provide write informed consent . The participant age 20 year old . The participant life expectancy &gt; 3 month . The participant adequate hematologic function , define : An absolute neutrophil count ( ANC ) &gt; 1500/cubic millimeter ( mm³ ) /microliter ( µL ) A hemoglobin level &gt; 10 grams/deciliter ( g/dL ) A platelet count &gt; 100,000/mm³ /µL The participant adequate hepatic function , define : A total bilirubin level &lt; 1.8 milligrams/deciliter ( mg/dL ) Aspartate transaminase ( AST ) level &lt; 86 International Units/liter ( IU/L ) Alanine transaminase ( ALT ) level ≤ 86 IU/L The participant adequate renal function , define : Serum creatinine level ≤ 1.5 mg/dL , Calculated serum creatinine clearance ( CockcroftGault ) ≥ 60 milliliters/minute ( mL/min ) The participant 's urinary protein 0 dipstick 1+ participant edema serum albumin &lt; low level normal ( LLN ) . The participant adequate coagulation function , define international normalized ratio ( INR ) ≤ 1.5 . The participant agree use adequate contraception study period 12 week last dose study treatment . The participant chemotherapy therapeutic radiotherapy within 28 day ( 6 week nitrosoureas mitomycin C ) prior enter study participant ongoing side effect ≥ Grade 2 due agent administer 28 day earlier . The participant obvious evidence intratumor cavitation . The participant undergone major surgery ( example , laparotomy , thoracotomy , removal organ [ ] ) within 28 day prior study entry , subcutaneous venous access device placement within 7 day prior study entry . The participant history postoperative bleeding complication wind complication surgical procedure . The participant elective plan surgery conduct trial . The participant document and/or symptomatic brain leptomeningeal metastasis . ( Participants clinically stable [ symptom 4 week prior enrollment ] assessment treatment [ radiation , surgical excision , administration steroid ] require , permit enter study . ) The participant uncontrolled intercurrent illness include , limited : Thrombotic hemorrhagic disorder Hemoptysis ( approximately onehalf teaspoon ) Ongoing active infection require systemic antibiotic treatment Congestive heart failure ( Class III IV New York Heart Association classification heart disease ) Angina pectoris , angioplasty , stenting , myocardial infarction within 6 month Uncontrolled hypertension ( systolic blood pressure &gt; 150 millimeter mercury ( mmHg ) , diastolic blood pressure &gt; 95 mm Hg ) Cardiac arrhythmia require treatment [ National Cancer Institute Common Terminology Criteria Adverse Events , Version 3.0 ( NCICTCAE v 3.0 ) , Grade 3 ] , asymptomatic sustain ventricular tachycardia ) Peripheral neuropathy etiology ≥ Grade 2 ( NCICTCAE v 3.0 ) The participant participate clinical study nonapproved experimental agent procedure within 4 week prior study entry small molecule , 8 week prior study entry nonapproved monoclonal antibody . The participant , female , pregnant ( confirmed urine serum pregnancy test ) lactating .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>recombinant human IgG1</keyword>
	<keyword>MAB</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>VEGFR 2</keyword>
	<keyword>human vascular endothelial growth factor receptor 2</keyword>
</DOC>